Shu‐Yein Ho

593 total citations
31 papers, 407 citations indexed

About

Shu‐Yein Ho is a scholar working on Hepatology, Epidemiology and Cancer Research. According to data from OpenAlex, Shu‐Yein Ho has authored 31 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 25 papers in Epidemiology and 12 papers in Cancer Research. Recurrent topics in Shu‐Yein Ho's work include Hepatocellular Carcinoma Treatment and Prognosis (30 papers), Liver Disease Diagnosis and Treatment (24 papers) and Cancer, Lipids, and Metabolism (12 papers). Shu‐Yein Ho is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (30 papers), Liver Disease Diagnosis and Treatment (24 papers) and Cancer, Lipids, and Metabolism (12 papers). Shu‐Yein Ho collaborates with scholars based in Taiwan, United States and Canada. Shu‐Yein Ho's co-authors include Teh‐Ia Huo, Po‐Hong Liu, Yi‐Hsiang Huang, Chien‐Wei Su, Chia‐Yang Hsu, Ming-Chih Hou, Cheng‐Yuan Hsia, Rheun‐Chuan Lee, Ming‐Chih Hou and Yun-Hsuan Lee and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Shu‐Yein Ho

31 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shu‐Yein Ho Taiwan	14	347	253	93	91	81	31	407
Yujing Xin China	12	200 0.6×	117 0.5×	66 0.7×	109 1.2×	52 0.6×	24	306
Yong‐Kang Diao China	11	252 0.7×	144 0.6×	88 0.9×	82 0.9×	87 1.1×	42	362
Nobuyoshi Tajiri Japan	9	237 0.7×	123 0.5×	106 1.1×	114 1.3×	79 1.0×	11	362
Soo Jeong Japan	9	195 0.6×	114 0.5×	25 0.3×	43 0.5×	83 1.0×	20	277
Chun‐Jung Lin Taiwan	9	177 0.5×	144 0.6×	24 0.3×	67 0.7×	122 1.5×	15	362
K. Thrum Germany	12	306 0.9×	168 0.7×	44 0.5×	57 0.6×	215 2.7×	21	399
Yoshirou Baba Japan	6	307 0.9×	218 0.9×	60 0.6×	38 0.4×	128 1.6×	9	393
Hao-Jan Lei Taiwan	12	252 0.7×	186 0.7×	67 0.7×	95 1.0×	135 1.7×	19	380
Masahiro Hatooka Japan	9	237 0.7×	129 0.5×	26 0.3×	35 0.4×	83 1.0×	15	289
Michinori Hamaoka Japan	10	190 0.5×	76 0.3×	68 0.7×	136 1.5×	77 1.0×	38	283

Countries citing papers authored by Shu‐Yein Ho

Since Specialization

Citations

This map shows the geographic impact of Shu‐Yein Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Yein Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Yein Ho more than expected).

Fields of papers citing papers by Shu‐Yein Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Yein Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Yein Ho. The network helps show where Shu‐Yein Ho may publish in the future.

Co-authorship network of co-authors of Shu‐Yein Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Yein Ho. A scholar is included among the top collaborators of Shu‐Yein Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Yein Ho. Shu‐Yein Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huo, Teh‐Ia & Shu‐Yein Ho. (2024). Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers. Hepatology Research. 55(4). 622–623. 1 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2023). Prognostic Prediction for Patients with Hepatocellular Carcinoma and Ascites: Role of Albumin-Bilirubin (ALBI) Grade and Easy (EZ)-ALBI Grade. Cancers. 15(3). 753–753. 7 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2023). Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency. International Journal of Molecular Sciences. 24(23). 16987–16987. 6 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2023). Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers. 15(7). 1925–1925. 13 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Cheng‐Yuan Hsia, et al.. (2022). Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade. International Journal of Clinical Oncology. 27(4). 739–748. 6 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2022). Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. Cancers. 14(17). 4207–4207. 6 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2021). Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatology Research. 51(11). 1129–1138. 16 indexed citations

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2021). Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology. 36(11). 3196–3203. 29 indexed citations

Ho, Shu‐Yein, Chia‐Yang Hsu, Po‐Hong Liu, et al.. (2020). Metavir Fibrosis Stage in Hepatitis C–Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. Journal of Gastrointestinal Surgery. 24(8). 1860–1862. 2 indexed citations

10.

Ho, Shu‐Yein, Chia‐Yang Hsu, Po‐Hong Liu, et al.. (2020). Albumin–Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive Diseases and Sciences. 66(5). 1730–1738. 13 indexed citations

11.

Ho, Shu‐Yein, Chia‐Yang Hsu, Po‐Hong Liu, et al.. (2020). Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers. 12(5). 1130–1130. 10 indexed citations

12.

Ho, Shu‐Yein, Chu-Chieh Chen, Po‐Hong Liu, et al.. (2020). Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. Digestive Diseases and Sciences. 65(11). 3389–3402. 5 indexed citations

13.

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2019). A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Digestive Diseases and Sciences. 65(2). 658–667. 11 indexed citations

14.

Ho, Shu‐Yein, Po‐Hong Liu, Cheng‐Yuan Hsia, et al.. (2019). Albumin‐bilirubin grade‐based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver International. 40(1). 205–214. 24 indexed citations

15.

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2018). Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Scientific Reports. 8(1). 843–843. 27 indexed citations

16.

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2018). Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Scientific Reports. 8(1). 4773–4773. 32 indexed citations

17.

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2018). Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Scientific Reports. 8(1). 15074–15074. 14 indexed citations

18.

Hsu, Chia‐Yang, Po‐Hong Liu, Shu‐Yein Ho, et al.. (2018). Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver International. 38(10). 1803–1811. 19 indexed citations

19.

Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2017). Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS ONE. 12(7). e0180408–e0180408. 33 indexed citations

20.

Hsu, Chia‐Yang, Po‐Hong Liu, Shu‐Yein Ho, et al.. (2017). Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS ONE. 12(11). e0188031–e0188031. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact